FDA approved a drug for sickle cell anemia that could pose a significant cost to state Medicaid budgets because a little more than half of the approximate 100,000 Americans living with sickle cell disease are in Medicaid and the annual cost of the drug is $84,852 to $113,136, based on list price. Novartis announced Friday (Nov. 15) the approval of Adakveo (crizanlizumab) to reduce the frequency of pain episodes in patients living with the genetic blood disorder. “Adakveo represents the...